APA (7th ed.) Citation

Deininger, M. W. N., & Müller, M. C. (2016). Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood, 127(6), . https://doi.org/10.1182/blood-2015-08-660977

Chicago Style (17th ed.) Citation

Deininger, Michael Werner Nikolaus, and Martin Christian Müller. "Compound Mutations in BCR-ABL1 Are Not Major Drivers of Primary or Secondary Resistance to Ponatinib in CP-CML Patients." Blood 127, no. 6 (2016). https://doi.org/10.1182/blood-2015-08-660977.

MLA (9th ed.) Citation

Deininger, Michael Werner Nikolaus, and Martin Christian Müller. "Compound Mutations in BCR-ABL1 Are Not Major Drivers of Primary or Secondary Resistance to Ponatinib in CP-CML Patients." Blood, vol. 127, no. 6, 2016, https://doi.org/10.1182/blood-2015-08-660977.